Displaying drugs 9151 - 9175 of 9937 in total
Phosphoaspartate
Experimental
Di-Stearoyl-3-Sn-Phosphatidylethanolamine
Experimental
3-Methyl-5-Sulfo-Pyrrolidine-2-Carboxylic Acid
Experimental
Diundecyl Phosphatidyl Choline
Experimental
Difluoromethionine
Experimental
2-Amino-3-Hydroxy-3-Phosphonooxy-Propionic Acid
Experimental
3-Chloro-4-Hydroxyphenylglycine
Experimental
Mdl-29951
Experimental
Di-Stearoyl-3-Sn-Phosphatidylcholine
Experimental
N-Methylleucine
Experimental
Fradafiban
Investigational
Tesaglitazar
Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Investigational
Lidorestat
Investigational
S-palmitoyl-L-cysteine
Experimental
Etofibrate
Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Experimental
Evacetrapib
Evacetrapib has been used in trials studying the basic science and treatment of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hepatic Insufficiency, and Cardiovascular Disease.
Investigational
GW842166
GW842166X has been used in trials studying the treatment of Pain, Analgesia, Inflammation, Osteoarthritis, and Pain, Inflammatory, among others.
Investigational
Displaying drugs 9151 - 9175 of 9937 in total